Core Viewpoint - Clearmind Medicine Inc. has announced the publication of six patents in Hong Kong, focusing on innovative combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds to address under-treated health issues [1][2][3] Group 1: Patent Publication and Innovations - The newly published patents protect formulations that combine PEA with MDMA, LSD, Ketamine, Ibogaine, Psilocybin, and DMT, aiming to enhance therapeutic potential and improve safety and tolerability for mental health and neurological conditions [2] - The company currently holds a total of nineteen patent families, which include 31 granted patents, and plans to seek additional patents as opportunities arise [5] Group 2: Company Strategy and Objectives - Clearmind is focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to tackle significant health problems, including alcohol use disorder [4] - The CEO emphasized the strategic combination of PEA with well-characterized psychedelics to build a robust pipeline of next-generation candidates aimed at addressing unmet needs in mental health [3]

A synthetic form of psilocybin—the active compound in magic mushrooms—can rapidly relieve symptoms of depression. Some patients responded as quickly as the following day https://t.co/jYQeXuKKev ...

Core Insights - The analysis of nearly 2,400 press releases from publicly traded companies indicates a strong focus on financing and product launches as key strategies for the upcoming business season [1] Group 1: Key Strategies - Financing & Capital Raises accounted for 25.5% of all announcements, highlighting a significant priority for companies [1] - Product Launches & Updates represented 24.8% of the announcements, indicating a strong emphasis on innovation and market presence [1] - Together, these two strategies comprised over 50% of all press releases, showcasing a clear trend in corporate communication [1]

Core Insights - Revive Therapeutics Ltd. is conducting a research study on Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada [1][2] - The study is ongoing, and final findings will be released with DRDC's authorization [2] - Revive is focused on developing therapeutics for infectious diseases and medical countermeasures, leveraging various FDA regulatory incentives [3] Company Overview - Revive Therapeutics specializes in the research and development of therapeutics for infectious diseases and medical countermeasures [3] - The company is exploring Bucillamine for nerve agent exposure and long COVID, alongside developing Psilocybin and molecular hydrogen therapeutics [3] Collaboration Details - The collaboration with DRDC provides expertise and infrastructure to support the development of medical countermeasures against nerve agent-induced brain injury [1]

Core Viewpoint - Revive Therapeutics Ltd. has successfully closed a second tranche of its private placement, raising gross proceeds of $91,400 by issuing 4,352,381 units at a price of $0.021 per unit [1][2]. Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The funds raised will be allocated for working capital and the payment of certain trade payables [2]. - All issued securities are subject to a hold period of four months and one day, expiring on January 19, 2026 [2]. Group 2: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [3]. - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, including treatments for nerve agent exposure [3]. - Revive is also advancing its Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science [3].

Core Insights - Revive Therapeutics Ltd. has successfully closed a second tranche of its private placement, issuing 4,352,381 units at a price of $0.021 per unit, resulting in gross proceeds of $91,400 [1][2] Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months post-closing [2] - The gross proceeds from this private placement will be allocated for working capital and the payment of certain trade payables [2] - All securities issued are subject to a hold period of four months and one day, expiring on January 19, 2026 [2] Group 2: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [3] - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, including treatments for nerve agent exposure [3] - Revive is also advancing its Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science [3]

Core Viewpoint - Revive Therapeutics Ltd. is extending its private placement offering to raise up to $650,000, with a first tranche already closed generating $60,900 [1][3]. Group 1: Private Placement Details - The private placement consists of up to 30,952,381 units priced at $0.021 per unit, with gross proceeds expected to be up to $650,000 [1]. - A first tranche of 2,900,000 units was issued at the same price, resulting in total gross proceeds of $60,900 [1]. - The company may close an additional $589,000 worth of units as part of this offering [1]. Group 2: Unit Composition and Terms - Each unit includes one common share and one common share purchase warrant, allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The issue price per unit is based on the 20-day volume-weighted average price (VWAP) of shares traded on the CSE [2]. Group 3: Use of Proceeds - Gross proceeds from the private placement will be allocated for working capital and payment of certain trade payables [3]. - The private placement may close in multiple tranches, subject to customary closing conditions [3]. Group 4: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement [4]. - The company is currently concentrating on Bucillamine for infectious diseases and medical countermeasures, as well as advancing Psilocybin and molecular hydrogen therapeutic programs [4].

As filed with the U.S. Securities and Exchange Commission on September 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (Primary Standard Industrial Classification Code Number) 269 David Brown Way Princeton, B.C. V0X 1W0 Canada (778) 761-4551 (Address, in ...

Psychedelics & Spirituality - An experiment revealed that 96% of religious participants considered a psilocybin trip among their top five most spiritually significant life experiences [1]

Core Viewpoint - Revive Therapeutics Ltd. has successfully closed the first tranche of its private placement offering, raising a total of $60,900 through the issuance of 2,900,000 units at a price of $0.021 per unit, while also settling a note payable through the issuance of additional units [1][2][3]. Group 1: Offering Details - The first tranche of the offering consisted of 2,900,000 units, generating gross proceeds of $60,900 for the company [1]. - Each unit comprises one common share and one common share purchase warrant, with the warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months [2]. - The company issued an additional 3,209,523 units to settle a note payable of $67,400, maintaining the same issue price of $0.021 per unit [1][3]. Group 2: Use of Proceeds - The gross proceeds from the offering will be allocated for working capital and the payment of certain trade payables [2]. Group 3: Compensation Options - In connection with the offering, the company issued 100,000 compensation options to an investment dealer, allowing the dealer to purchase units at a price of $0.05 for 18 months [4]. - Each compensation unit consists of one common share and one-half of a common share purchase warrant, with the whole warrant allowing acquisition of one compensation share at an exercise price of $0.05 for 36 months [5]. Group 4: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [6]. - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, as well as advancing its Psilocybin and molecular hydrogen therapeutic programs [6].